These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 37241929)

  • 21. The potential roles of natural plant polysaccharides in inflammatory bowel disease: A review.
    Yang W; Zhao P; Li X; Guo L; Gao W
    Carbohydr Polym; 2022 Feb; 277():118821. PubMed ID: 34893238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
    Qiu X; Ma J; Wang K; Zhang H
    Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mesalamine protects against colorectal cancer in inflammatory bowel disease.
    Tang J; Sharif O; Pai C; Silverman AL
    Dig Dis Sci; 2010 Jun; 55(6):1696-703. PubMed ID: 19705280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature.
    Wang R; Leong RW
    World J Gastroenterol; 2014 Jul; 20(27):8783-9. PubMed ID: 25083052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Non-Starch Polysaccharides on Inflammatory Bowel Disease.
    Nie Y; Lin Q; Luo F
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28654020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioengineered Colorectal Cancer Drugs: Orally Delivered Anti-Inflammatory Agents.
    Urbanska AM; Zhang X; Prakash S
    Cell Biochem Biophys; 2015 Jul; 72(3):757-69. PubMed ID: 27352189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastroprotective Effects of Polyphenols against Various Gastro-Intestinal Disorders: A Mini-Review with Special Focus on Clinical Evidence.
    Chiu HF; Venkatakrishnan K; Golovinskaia O; Wang CK
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33917379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use.
    Samadder NJ; Mukherjee B; Huang SC; Ahn J; Rennert HS; Greenson JK; Rennert G; Gruber SB
    Cancer; 2011 Apr; 117(8):1640-8. PubMed ID: 21472711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural Polyphenols for Treatment of Colorectal Cancer.
    Zhang Y; Liu K; Yan C; Yin Y; He S; Qiu L; Li G
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases.
    Piechota-Polanczyk A; Fichna J
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Jul; 387(7):605-20. PubMed ID: 24798211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orally administrable polyphenol-based nanoparticles achieve anti-inflammation and antitumor treatment of colon diseases.
    Le Z; He Z; Liu H; Ke J; Liu L; Liu Z; Chen Y
    Biomater Sci; 2022 Jul; 10(15):4156-4169. PubMed ID: 35726761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chrysophanol Attenuates Manifestations of Immune Bowel Diseases by Regulation of Colorectal Cells and T Cells Activation In Vivo.
    Lee HS; Jeong GS
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33802855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines.
    Porter RJ; Arends MJ; Churchhouse AMD; Din S
    J Crohns Colitis; 2021 Dec; 15(12):2131-2141. PubMed ID: 34111282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol and inflammatory bowel disease: the evidence so far.
    Nunes S; Danesi F; Del Rio D; Silva P
    Nutr Res Rev; 2018 Jun; 31(1):85-97. PubMed ID: 29191255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
    Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
    Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Biomarkers for Inflammatory Bowel Disease and Colorectal Cancer: An Interplay between Metabolic Dysregulation and Excessive Inflammation.
    Salla M; Guo J; Joshi H; Gordon M; Dooky H; Lai J; Capicio S; Armstrong H; Valcheva R; Dyck JRB; Thiesen A; Wine E; Dieleman LA; Baksh S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease.
    Goessling W; Mayer RJ
    Gastroenterol Clin North Am; 2006 Sep; 35(3):713-27. PubMed ID: 16952747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review.
    Sałaga M; Zatorski H; Sobczak M; Chen C; Fichna J
    Curr Treat Options Oncol; 2014 Sep; 15(3):405-20. PubMed ID: 24792017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes.
    Tomasello G; Tralongo P; Damiani P; Sinagra E; Di Trapani B; Zeenny MN; Hussein IH; Jurjus A; Leone A
    World J Gastroenterol; 2014 Dec; 20(48):18121-30. PubMed ID: 25561781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
    Chan EP; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.